Trial: 201402042

A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome

Phase

I/II

Principal Investigator

Uy, Geoffrey

Disease Site

Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov